Last reviewed · How we verify
NCT05893693
Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NA trial testing Biological in Relapsed and/or Refractory Multiple Myeloma in 12 participants. Status unknown.
1 January 2026
Quick facts
| Lead sponsor | Aibin Liang，MD，Ph.D. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 12 April 2023 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Biological — full drug profile →
Conditions studied
- Relapsed and/or Refractory Multiple Myeloma — all drugs for Relapsed and/or Refractory Multiple Myeloma →
- Plasma Cell Leukemia in Relapse — all drugs for Plasma Cell Leukemia in Relapse →
Sponsor
Aibin Liang，MD，Ph.D. — full company profile →
Who can join
Adults 18 to 75, any sex, with Relapsed and/or Refractory Multiple Myeloma or Plasma Cell Leukemia in Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05893693
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological
Trials testing the same drug.
- NCT06444503 — Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies · recruiting
- NCT05608148 — Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors · Phase 1 · recruiting
- NCT05207371 — Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC · Phase 1, PHASE2 · unknown
- NCT04542967 — Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease · Phase 2 · completed
- NCT03327493 — Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO · NA · completed
Other recruiting trials for Relapsed and/or Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT06153251 — A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06182696 — OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM · Phase 1, PHASE2 · recruiting
- NCT03715478 — Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex · Phase 1, PHASE2 · active not recruiting
Other Aibin Liang，MD，Ph.D. trials
Trials by the same sponsor.
- NCT06734871 — A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT05842707 — Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05893693 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aibin Liang，MD，Ph.D.
- Last refreshed: 8 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05893693.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing